Posts tagged with ‘ISO-CC-005’

  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an…

    by
  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by